Featured Press Releases

NewAmsterdam Pharma announces positive topline data from the Phase 3 BROOKLYN trial of Obicetrapib in heterozygous familial hypercholesterolemia patients

NewAmsterdam Pharma announces positive topline data from the Phase 3 BROOKLYN trial of Obicetrapib in heterozygous familial hypercholesterolemia patients

Galmed releases Phase 3 Aramchol results in Hepatology.

Galmed releases Phase 3 Aramchol results in Hepatology.

  • 26 Sep 2024

Galmed Pharmaceuticals Ltd. a clinical-stage biopharmaceutical company for liver, metabolic and...

LatigoBio_Logo

"Latigo Biotherapeutics has been granted FDA Fast Track Designation for LTG-001, a potential best-in-class Nav1.8 inhibitor for the non-opioid treatment of acute pain

Novotech receives new investment from GIC, Temasek, and existing investor TPG to accelerate global growth

Novotech receives new investment from GIC, Temasek, and existing investor TPG to accelerate global growth

Merz Aesthetics launches Ultherapy PRIME, the next generation of nonsurgical skin lifting treatments

Merz Aesthetics launches Ultherapy PRIME, the next generation of nonsurgical skin lifting treatments

Nested Therapeutics Receives FDA Clearance for IND Application of NST-628, a Groundbreaking Pan-RAF/MEK Molecular Glue

Nested Therapeutics Receives FDA Clearance for IND Application of NST-628, a Groundbreaking Pan-RAF/MEK Molecular Glue

New long-term data confirms TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to block joint damage in active psoriatic arthritis

New long-term data confirms TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to block joint damage in active psoriatic arthritis

  • Johnson & Johnson
  • 17 Nov 2025
Marius Pharmaceuticals has expanded its global footprint with Health Canada’s approval of KYZATREX® (testosterone undecanoate) CIII capsules

Marius Pharmaceuticals has expanded its global footprint with Health Canada’s approval of KYZATREX® (testosterone undecanoate) CIII capsules

  • Marius Pharmaceuticals LLC
  • 13 Nov 2025
The BioTech Breakthrough Award has been granted to Asahi Kasei for the Planova™ FG1 Filter

The BioTech Breakthrough Award has been granted to Asahi Kasei for the Planova™ FG1 Filter

  • Asahi Kasei
  • 13 Nov 2025
Odyssey Therapeutics Welcomes Dennis Dean, Ph.D., as EVP, Non-Clinical Development

Odyssey Therapeutics Welcomes Dennis Dean, Ph.D., as EVP, Non-Clinical Development

  • Odyssey Therapeutics, Inc.
  • 11 Nov 2025
HanchorBio Unveils Compelling New Data at SITC 2025 Highlighting the Best-in-Class Potential of HCB101 in Advanced Cancers

HanchorBio Unveils Compelling New Data at SITC 2025 Highlighting the Best-in-Class Potential of HCB101 in Advanced Cancers

  • HanchorBio Inc.
  • 10 Nov 2025
VTAMA® (tapinarof) Cream, 1%, Demonstrates Early and Consistent Efficacy in Children Aged 2+ with Atopic Dermatitis, According to New Data

VTAMA® (tapinarof) Cream, 1%, Demonstrates Early and Consistent Efficacy in Children Aged 2+ with Atopic Dermatitis, According to New Data

  • Organon & Co.
  • 10 Nov 2025

Most Popular
November   2025
M T W T F S S
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

User Area

Discover

Engage with Us

© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.